Tempus

We will report financial results for the second quarter ended June 30, 2026, on Thursday, July 30, 2026 at 4:30 p.m. ET. The conference call and live audio webcast will discuss the quarter’s results and provide a business update, led by Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the “Events” section of the Tempus Investor Relations website or by clicking here:

A new case study details how we constructed a retrospective, multimodal data cohort to serve as an external control arm for a biotech company’s Phase 1b/2a mNSCLC trial. By leveraging longitudinal EHR data, genomic insights, and independent radiographic reviews based on RECIST 1.1 criteria, we established a robust standard of care benchmark. Access the full case study and discover how we can help accelerate your research here: tempus.co/4p7p9Jj

New research in the Lens Library displays how real-world liquid biopsy data can monitor tumor dynamics in real time to uncover crucial prognostic insights for non-small cell lung cancer (#NSCLC). Using the Tempus Lens platform to analyze multimodal data alongside the Tempus xF liquid biopsy assay, researchers evaluated ctDNA fractions in NSCLC patients both pre-treatment and post-initiation of first-line (1L) therapy. Access the full study here: tempus.co/4fccD7Y

Dr. Alan Tan, Vice President of MRD Research and Clinical Strategy at Tempus sat down with Dr. Luis Raez, Medical Director at Memorial Cancer Institute to explore how ctDNA-based #MRDtesting can support prognosis, recurrence monitoring, and treatment response assessment across the cancer care continuum. Read their discussion, including how Tempus’ tumor-naive and tumor-informed solutions can be applied in practice, here: tempus.co/4geZ5cO

We are excited to announce a research collaboration with Angiosarcoma Awareness, Inc. to accelerate data-driven research in angiosarcoma, one of the rarest and most aggressive cancers. Read on: tempus.co/4f3LuUA

"Your research should move at the speed of your hypothesis, not the speed of your code." Watch as Dayana Delgado, PhD, a Translational Scientist at Tempus, uses Tempus Lens to accelerate RNA expression analysis, moving from a complex research question to a publication-ready visualization in minutes. Lens allows you to replace hours of manual coding with an instant, reproducible result, all without writing a single line of code. Request access now: tempus.co/4wapJZg

Tempus and @bmsnews leaders recently discussed a real-world, advanced non-small cell lung cancer (#aNSCLC) case study. By deploying the Tempus Next Pathways platform across 13 community-based health systems, we were able to unlocke a unified, longitudinal view of the patient journey. This drove an 8% lift in guideline-directed biomarker testing. A recording of the webinar is available for viewing here: tempus.co/4ecOAFG

In an upcoming webinar, Kate Sasser, PhD, Chief Scientific Officer, Tempus and Razik Yousfi, SVP & GM, AI Products, Tempus, will discuss how AI-driven tools are unlocking insights from standard H&E slides to de-risk patient selection and how a holistic, data-driven approach can help design the next generation of successful #ADCs. Register now: tempus.co/3S8Wnf2

Precision medicine requires data that evolves with patients. By integrating comprehensive molecular profiling with deep clinical data, we are delivering the insights needed to drive more informed, personalized care across the entire cancer continuum. Discover our solutions: tempus.co/44hYEXP

A recording of our #AACR26 Exhibitor Spotlight is now available. Kate Sasser, PhD, Chief Scientific Officer at Tempus, and Neil Bence, PhD, of @bmsnews discuss how #AI and #RWD are shaping the future of oncology drug development. Access now: tempus.co/4xtkdSL

“I think that’s a key component of this, and you know we have done some work within our own health system within one EMR, and that’s exciting but really limited. And what Tempus was able to do is they really have created something that can go across multiple EMRs.” – Dr. Melina E. Marmarelis From an interview published by @ASCO AI in Oncology on the #ASCO26 study, "Multi-center prospective study evaluating an AI-enabled clinical decision support tool to improve biomarker testing in early-stage NSCLC." The study demonstrated clinically meaningful improvements in biomarker testing rates following the implementation of Tempus Next. bit.ly/4uByg5X

Multi-site validation of our ECG-AF software, which received U.S. Food and Drug Administration clearance for predicting the one-year risk of atrial fibrillation or flutter, was published in @hrs_journal. The study evaluated the Tempus ECG-AF software across three geographically distinct clinical sites and demonstrates the promising avenue for improving diagnosis that the application of AI to electrocardiogram interpretation offers. Read on: tempus.co/heart-rhythm-e…

Tempus researchers sought to investigate how PRAME expression levels correlate with real-world survival outcomes when patients are treated with a combination of immunotherapy and chemotherapy in the first-line setting. Explore the analysis and its results in the Lens Library now: tempus.co/4u7wycB

Lines of therapy are a key anchor for benchmarking therapy performance and informing R&D strategy, including when comparing patient outcomes and drug effectiveness over time and across cohorts. In a new article we detail the expert-vetted, rules-based approach to standardizing line of therapy capture for #oncologyresearch. This standardized foundation enables researchers to proceed directly to analysis with confidence. Read now: tempus.co/4aiujMi

So proud to see two of the top pharmaceutical CEOs in the world, Pascal Soriot, CEO of @AstraZeneca, and Rob Davis, CEO of @Merck, recently highlight their strategic partnerships with Tempus to bring the power and promise of artificial intelligence to oncology. bit.ly/4ofFHOF bit.ly/4vBGgVD

Our single, research-ready dataset gives you a complete picture by unifying connected clinical histories, rich multimodal biology, and a representative patient population. Assess your cohort’s feasibility with our RWD by submitting your preliminary criteria, and our team will provide a tailored feasibility assessment to help accelerate your research goals: tempus.co/4uduyzn

#ASCO26 has come to a close and we're grateful for an impactful weekend in Chicago spent with colleagues and the greater oncology community. Check out some highlights below, including the presentations of our largest collection of accepted research to date, an engaging Industry Expert Theater, and four days of conversations and demos at our booth. You can find more information about our presence at ASCO here: tempus.co/3RZyVAD